Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03702582 · ClinicalTrials.gov registry record · Phase 3
Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT03702582: Completed Phase 3 study, sponsored by Massachusetts General Hospital.
NCT03702582 is a Phase 3 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03702582, a Phase 3 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
This prospective, randomized, active-controlled, parallel arm study compares the safety and financial benefits of arterial thromboembolism prophylaxis with Warfarin vs. Rivaroxaban (A novel oral anticoagulant) in patients with new onset atrial fibrillation after sternotomy for cardiac operations.
Interventions
- DRUG Warfarin
- DRUG Rivaroxaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-04-30 |
| Est. Completion | 2023-10-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03702582
The ClinicalTrials.gov registry entry for NCT03702582 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Warfarin is the first listed.
NCT03702582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03702582 about?
NCT03702582 is a clinical study titled "Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation". This prospective, randomized, active-controlled, parallel arm study compares the safety and financial benefits of arterial thromboembolism prophylaxis with Warfarin vs. Rivaroxaban (A novel oral anticoagulant) in patients with new onset atrial fibrillation after sternotomy for cardiac operations.
What is the current status of trial NCT03702582?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2019-04-30. Estimated completion is 2023-10-01.
What interventions are being tested in trial NCT03702582?
The interventions under investigation include: Warfarin (DRUG), Rivaroxaban (DRUG).
Who is sponsoring clinical trial NCT03702582?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.